Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of multiple sclerosis
3.2.1.2 Advancements in drug development
3.2.1.3 Growing focus on personalized medicine
3.2.1.4 Rising geriatric population
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of the drugs
3.2.2.2 Side effects associated with the medication
3.3 Growth potential analysis
3.4 Technology landscape
3.5 Pipeline analysis
3.6 Regulatory landscape
3.7 Future market trends
3.8 Porter’s analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Immunosuppressants
5.3 Immunostimulants
5.4 Immunomodulators
5.5 Corticosteroids
5.6 Other drug classes
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Oral
6.3 Injectables
6.3.1 Intramuscular
6.3.2 Subcutaneous
6.3.3 Intravenous
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospital pharmacy
7.3 Retail pharmacy
7.4 Online pharmacy
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 Abbvie Inc.
9.2 Amgen Inc.
9.3 Acorda Therapeutics, Inc.
9.4 Biogen Inc.
9.5 Bayer AG
9.6 Bristol-Myers Squibb Company.
9.7 F. Hoffman-La Roche Ltd
9.8 Johnson & Johnson
9.9 Merck & Co., Inc.
9.10 Novartis AG
9.11 Teva Pharmaceutical Industries Ltd.
9.12 Takeda Pharmaceuticals Company Limited.
9.13 Pfizer Inc.
9.14 Sanofi
9.15 Viatris Inc.
